immune system
• fMLP-treated mice exhibit fewer neutrophils, monocytes, and lymphocytes in the air pouch and cardiac puncture compared to in similarly treated wild-type mice
• fMLP-treated neutrophils exhibit impaired uropod formation compared with similarly treated wild-type cells
|
• MIP-2 (Cxcl2)-treated neutrophils exhibit impaired chemotaxis into Matrigel compared with similarly treated wild-type cells
• however, fMLP-treated neutrophils exhibit normal chemotax on glass and chemoattractant sensing is normal
|
homeostasis/metabolism
• MEFs transfected with GFP-APPswe and treated with antiserum to GFP show a slight but significant reduction in antibody uptake
• no colocalization of flotillin1 with APPswe
|
cellular
• MIP-2 (Cxcl2)-treated neutrophils exhibit impaired chemotaxis into Matrigel compared with similarly treated wild-type cells
• however, fMLP-treated neutrophils exhibit normal chemotax on glass and chemoattractant sensing is normal
|
nervous system
• MEFs transfected with GFP-APPswe and treated with antiserum to GFP show a slight but significant reduction in antibody uptake
• no colocalization of flotillin1 with APPswe
|
hematopoietic system
• fMLP-treated mice exhibit fewer neutrophils, monocytes, and lymphocytes in the air pouch and cardiac puncture compared to in similarly treated wild-type mice
• fMLP-treated neutrophils exhibit impaired uropod formation compared with similarly treated wild-type cells
|
• MIP-2 (Cxcl2)-treated neutrophils exhibit impaired chemotaxis into Matrigel compared with similarly treated wild-type cells
• however, fMLP-treated neutrophils exhibit normal chemotax on glass and chemoattractant sensing is normal
|